Guidant Looking Beyond Boston Scientific's Paclitaxel Stent Dispute
This article was originally published in The Gray Sheet
Executive Summary
Cook's ability to establish Guidant as a "distributor" rather than a licensee of its paclitaxel application technology should result in a favorable outcome in the drug-coated stent dispute brought by Boston Scientific, Guidant claims.
You may also be interested in...
Drug-Coated Stents May Get ICD-9 Code In Time For Cypher Approval In 2003
Drug-eluting coronary stents are likely to receive a unique ICD-9-CM code in time for the first FDA approval of the devices, expected by Johnson & Johnson/Cordis in 2003
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.